Pelthos TherapeuticsPTHS +1.31%8 Receivables Turnover is 1.06 as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, Pelthos Therapeutics ranks worse than 76.64% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pelthos Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $10.91 Mil. Pelthos Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $10.28 Mil.
Hence, Pelthos Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.06.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pelthos Therapeutics Receivables Turnover Related Terms
Pelthos Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pelthos Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTHS vs CGTX, BDTX, CBUS: Receivables Turnover Comparison
For the Biotechnology subindustry, Pelthos Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pelthos Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pelthos Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pelthos Therapeutics (PTHS) has a Receivables Turnover of 1.06 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pelthos Therapeutics and its competitors. According to the industry distribution chart, Pelthos Therapeutics ranks #643 out of 839 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Pelthos Therapeutics' Receivables Turnover too high?
Pelthos Therapeutics' current Receivables Turnover is 1.06. The Biotechnology industry median Receivables Turnover is 5.27. Pelthos Therapeutics' value of 1.06 is 79.9% below this industry median. Based on the distribution chart, Pelthos Therapeutics ranks #643 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Receivables Turnover compare to CGTX and BDTX?
According to the Biotechnology industry distribution chart, Pelthos Therapeutics ranks #643 out of 839 companies for Receivables Turnover. This places Pelthos Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.27. Pelthos Therapeutics' value of 1.06 is 79.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pelthos Therapeutics's current Receivables Turnover of 1.06 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pelthos Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pelthos Therapeutics's current Receivables Turnover is 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Receivables Turnover of 1.06. The current Receivables Turnover is 1.06 and 79.9% below the Biotechnology industry median of 5.27. Pelthos Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Receivables Turnover is 1.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score
Get the complete analysis for PTHS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTHS has been successfully added to your 
